Essex Woodlands Management, Inc. - Q4 2013 holdings

$199 Million is the total value of Essex Woodlands Management, Inc.'s 11 reported holdings in Q4 2013. The portfolio turnover from Q3 2013 to Q4 2013 was 0.0% .

 Value Shares↓ Weighting
ABMD  ABIOMED INC$84,231,000
+40.3%
3,150,0000.0%42.34%
+6.8%
HZNP  HORIZON PHARMA INC$42,117,000
+133.8%
5,815,9400.0%21.17%
+78.0%
ELGX  ENDOLOGIX INC$35,549,000
+4.5%
1,165,4280.0%17.87%
-20.5%
ACUR  ACURA PHARMACEUTICALS INC$16,396,000
-13.0%
10,294,8860.0%8.24%
-33.8%
ZIOP  ZIOPHARM ONCOLOGY INC$11,330,000
+16.6%
2,764,9080.0%5.70%
-11.3%
CO SellCHINA CORD BLOOD CORP$3,096,000
-21.5%
974,200
-6.1%
1.56%
-40.2%
SLTM SellSOLTA MED INC$3,009,000
+9.3%
1,020,219
-23.3%
1.51%
-16.8%
MNOV  MEDICINOVA INC$2,505,000
-16.7%
1,170,3700.0%1.26%
-36.6%
CRIS  CURIS INC$659,000
-36.8%
233,7970.0%0.33%
-52.0%
ECTE  ECHO THERAPEUTICS INC$39,000
+14.7%
12,3190.0%0.02%
-9.1%
PTN  PALATIN TECHNOLOGIES INC$18,000
+5.9%
23,9280.0%0.01%
-18.2%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2014-02-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
MEDICINOVA INC42Q3 20236.5%
REVANCE THERAPEUTICS INC39Q3 202344.6%
AXOGEN INC26Q4 202143.3%
ENDOLOGIX INC24Q1 201922.5%
ABIOMED INC20Q1 201852.1%
CORIUM INTL INC20Q1 201923.5%
TELA BIO, INC.16Q3 202331.5%
VENUS CONCEPT, INC.16Q3 202321.3%
ACURA PHARMACEUTICALS INC15Q1 20191.4%
CATALYST BIOSCIENCES INC15Q1 20191.0%

View Essex Woodlands Management, Inc.'s complete holdings history.

Latest filings
TypeFiled
13F-HR2024-02-14
13F-HR2023-11-14
13F-HR2023-08-14
13F-HR2023-05-15
13F-HR2023-02-14
13F-HR2022-11-14
13F-HR2022-08-15
13F-HR2022-05-16
13F-HR2022-02-14
13F-HR2021-11-15

View Essex Woodlands Management, Inc.'s complete filings history.

Compare quarters

Export Essex Woodlands Management, Inc.'s holdings